JGC
ESPR

J. Goldman & Co’s Esperion Therapeutics ESPR Stock Holding History

J. Goldman & Co’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-472,500
Closed -$2.94M – 389
2022
Q4 		$2.94M Buy
+472,500
New +$3.38M 0.14% 148
2020
Q3 		– Sell
-45,000
Closed -$2.31M – 330
2020
Q2 		$2.31M Buy
+45,000
New +$1.88M 0.14% 149
2020
Q1 		– Sell
-2,700
Closed -$161K – 271
2019
Q4 		$161K Buy
+2,700
New +$121K 0.01% 241
2018
Q2 		– Sell
-65,000
Closed -$4.7M – 376
2018
Q1 		$4.7M Sell
65,000
-182,000
-74% -$13.4M 0.2% 130
2017
Q4 		$16.3M Buy
247,000
+195,000
+375% +$10.5M 0.85% 30
2017
Q3 		$2.61M Buy
52,000
+37,000
+247% +$1.78M 0.13% 173
2017
Q2 		$694K Buy
+15,000
New +$552K 0.04% 231

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

J. Goldman & Co's ESPR Position: Q1 2023 in Review

J. Goldman & Co sold out of Esperion Therapeutics (ESPR) in Q1 2023, closing a stake of 293,864 shares — an estimated $1.83M sold.

J. Goldman & Co first reported a position in ESPR in Q4 2016 and held it in 14 quarters. The position peaked at $3.71M in Q1 2018. 164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

  • J. Goldman & Co reported no remaining Esperion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • J. Goldman & Co sold 293,864 Esperion Therapeutics shares in Q1 2023, an estimated $1.83M.
  • J. Goldman & Co first reported a position in Esperion Therapeutics in Q4 2016 and held it in 14 quarters.
  • J. Goldman & Co's Esperion Therapeutics position peaked at $3.71M in Q1 2018.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on J. Goldman & Co's 13F filing for Q1 2023, filed 15 May 2023.